08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Archexin: Interim Phase IIa data

Interim data from about 9 patients with metastatic RCC in the first stage of a 2-stage, open-label Phase IIa trial showed that once-daily 125, 200 and 250 mg/m 2 IV Archexin plus Afinitor everolimus...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

Archexin: Phase IIa started

Rexahn began a 2-stage Phase IIa trial of Archexin plus Afinitor everolimus. A dose-escalation portion in up to 3 cohorts of 3 patients with metastatic RCC will determine the maximum tolerated dose (MTD). The...
08:00 , Jan 20, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celltrion Inc. (KOSDAQ:068270) lost W350 to W45,650 last week after South Korea's Ministry of Food and Drug Safety (MFDS) approved Herzuma trastuzumab as a biosimilar of Herceptin trastuzumab to treat early and advanced HER2-positive...
00:47 , Jan 16, 2014 |  BC Extra  |  Financial News

Rexahn planning $20 million direct offering

Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) plans to raise about $20 million through the sale of about 19.1 million units at $1.05 in a registered direct offering. Each unit comprises a share and a five-year warrant to...
07:00 , Sep 3, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.20 to $20.56 last week after submitting an MAA to EMA for ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

Archexin: Phase IIa data

Top-line data from a single-arm, open-label, U.S. and Indian Phase IIa trial in 31 patients aged 18-65 with metastatic pancreatic cancer showed that Archexin plus gemcitabine led to a median OS, the primary endpoint, of...
23:26 , Aug 28, 2012 |  BC Extra  |  Clinical News

Rexahn reports top-line data for Archexin in pancreatic cancer

Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) reported top-line data from a single-arm, open-label Phase IIa trial in 31 patients with metastatic pancreatic cancer showing that Archexin plus gemcitabine led to a median overall survival (OS) of 9.1...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Clinical News

Archexin: Completed Phase II enrollment

Rexahn completed enrollment of about 35 patients with metastatic pancreatic cancer in a single-arm, open-label, U.S. and Indian Phase II trial evaluating 250 mg/m 2/day IV Archexin for the first 2 weeks of a 3-week...
00:48 , Mar 29, 2011 |  BC Extra  |  Financial News

Rexahn raises $10 million

Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) raised $10 million through the sale of 8.3 million units at $1.20 in a registered direct offering. Each unit comprises a share and a five-year warrant to purchase 0.4 shares, with...